Replimune Group, Inc.
REPL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737953
In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 5 sales; 199 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Replimune Group, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 4 insiders, $1.04M in total
- Insiders trading
- 4
- Net value
- −$1.04M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Replimune Group, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Astley-Sparke Philip | Director | 1,362,414 | Aug 24, 2026 | 4 |
| Hill Emily Luisa | Chief Financial Officer | 215,852 | Aug 19, 2026 | 5 |
| Patel Sushil | Chief Executive Officer | 708,151 | Aug 12, 2026 | 5 |
| Xynos Konstantinos | Chief Medical Officer | 224,215 | Aug 12, 2026 | 5 |
| Schwendenman Andrew | Chief Accounting Officer | 99,425 | Aug 12, 2026 | 4 |
| Baker Julian | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Baker Felix | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Baker Bros. Advisors LP | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Baker Brothers Life Sciences LP | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| 667, L.P. | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | – | Aug 11, 2026 | 2 |
| Sarchi Christopher | Chief Commercial Officer | 180,962 | Jun 3, 2026 | 6 |
| Slattery Joseph P | Director | – | Apr 7, 2026 | 1 |
| Pucci Paolo | Director | – | Apr 7, 2026 | 1 |
| Dhingra Kapil | Director | 0 | Apr 7, 2026 | 2 |
| Balachandran Madhavan | Director | – | Apr 7, 2026 | 1 |
| Weinand Dieter | Director | – | Apr 7, 2026 | 1 |
| Oliger Christy J. | Director | – | Apr 7, 2026 | 1 |
| Peeples-Dyer Veleka | Director | – | Apr 7, 2026 | 1 |
| Coffin Robert | Director | 1,821,872 | May 20, 2024 | 0 |
| Love Colin | Chief Operating Officer | 777,345 | May 20, 2024 | 0 |
| Levitsky Hyam | Director | – | Apr 3, 2024 | 0 |
| Esposito Pamela | Chief Business Officer | 263,436 | Sep 13, 2023 | 0 |
| Lewis Tanya | Chief Dev. Op. Officer | 135,293 | Jun 15, 2023 | 0 |
| Franchi Jean M. | Chief Financial Officer | 128,748 | May 18, 2023 | 0 |
| Slootweg Hugo Alexander | Director | – | Apr 4, 2023 | 0 |
| Rhodes Jason P | Director | – | Apr 5, 2022 | 0 |
| Stampacchia Otello | 10% Owner | 4,673,380 | Mar 16, 2022 | 0 |
| Omega Fund IV, L.P. | 10% Owner | 4,673,380 | Mar 16, 2022 | 0 |
| Omega Fund IV GP, L.P. | 10% Owner | 4,673,380 | Mar 16, 2022 | 0 |
| Omega Fund IV G.P. Manager, Ltd. | 10% Owner | 4,673,380 | Mar 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 (view filing)6:42 PM ET | Aug 17 | 2 days | Hill Emily LuisaChief Financial Officer | SSale | −9.26K | $14.28 | −$132.2K | −4.1%215.9K after | |
| Aug 12, 2026 (view filing)5:07 PM ET | Aug 10 | 2 days | Patel SushilChief Executive Officer | SSale | −39.3K | $12.97 | −$510.3K | −5.3%708.2K after | |
| Aug 12, 2026 (view filing)5:06 PM ET | Aug 10 | 2 days | Hill Emily LuisaChief Financial Officer | SSale | −11.4K | $12.97 | −$148.5K | −4.8%225.1K after | |
| Aug 12, 2026 (view filing)5:05 PM ET | Aug 10 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −11.4K | $12.97 | −$148.5K | −4.9%224.2K after | |
| Aug 12, 2026 (view filing)5:04 PM ET | Aug 10 | 2 days | Schwendenman AndrewChief Accounting Officer | SSale | −7.63K | $12.97 | −$99.0K | −7.1%99.4K after | |
| Aug 11, 2026 (view filing)5:46 PM ET | Aug 11 | Same day | Baker Julian and 5 othersDirector, 10% Owner | PPurchase | +2.74M | $12.06 | +$33.0M | –2.61M after | Derivative2 lots |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Sarchi ChristopherChief Commercial Officer | SSale | −12.0K | $9.24 | −$110.9K | −6.2%181.0K after | 10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −14.0K | $5.08 | −$71.2K | −5.6%235.7K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Schwendenman AndrewChief Accounting Officer | SSale | −7.89K | $5.08 | −$40.1K | −6.9%107.1K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Sarchi ChristopherChief Commercial Officer | SSale | −8.63K | $5.08 | −$43.8K | −4.3%193.0K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Astley-Sparke PhilipDirector | SSale | −17.7K | $5.08 | −$89.7K | −1.2%1.41M after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Patel SushilChief Executive Officer | SSale | −37.3K | $5.08 | −$189.6K | −4.8%747.5K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Hill Emily LuisaChief Financial Officer | SSale | −7.81K | $5.08 | −$39.7K | −3.2%236.6K after | |
| Apr 6, 2026 (view filing) | Apr 2 | 4 days | Sarchi ChristopherChief Commercial Officer | SSale | −6.50K | $8.01 | −$52.1K | −4.1%151.6K after | 10b5-1 |
| Dec 11, 2025 (view filing) | Dec 9 | 2 days | Dhingra KapilDirector | SSale | −3.17K | $10.40 | −$33.0K | −100.0%0 after | |
| Dec 4, 2025 (view filing) | Dec 2 | 2 days | Patel SushilChief Executive Officer | SSale | −10.0K | $11.13 | −$111.3K | −2.9%333.6K after | 10b5-1 |
| Nov 19, 2025 (view filing) | Nov 17 | 2 days | Sarchi ChristopherChief Commercial Officer | SSale | −5.21K | $9.10 | −$47.4K | −4.1%123.1K after | |
| Nov 19, 2025 (view filing) | Nov 17 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −7.25K | $9.10 | −$66.0K | −4.9%139.7K after | |
| Aug 19, 2025 (view filing) | Aug 15 | 4 days | Hill Emily LuisaChief Financial Officer | SSale | −9.15K | $5.37 | −$49.2K | −6.4%134.4K after | |
| May 22, 2025 (view filing) | May 20 | 2 days | Astley-Sparke PhilipDirector | SSale | −32.3K | $8.06 | −$260.2K | −2.2%1.41M after | |
| May 22, 2025 (view filing) | May 20 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −7.95K | $8.06 | −$64.1K | −5.1%146.9K after | |
| May 22, 2025 (view filing) | May 20 | 2 days | Schwendenman AndrewChief Accounting Officer | SSale | −3.29K | $8.05 | −$26.5K | −4.6%68.3K after | |
| May 22, 2025 (view filing) | May 20 | 2 days | Patel SushilChief Executive Officer | SSale | −25.1K | $8.06 | −$202.3K | −6.8%343.6K after | |
| May 22, 2025 (view filing) | May 20 | 2 days | Hill Emily LuisaChief Financial Officer | SSale | −2.54K | $8.05 | −$20.4K | −1.7%143.5K after | |
| May 22, 2025 (view filing) | May 20 | 2 days | Sarchi ChristopherChief Commercial Officer | SSale | −3.75K | $8.05 | −$30.2K | −2.8%128.3K after | |
| Dec 18, 2024 (view filing) | Dec 16 | 2 days | Patel SushilChief Executive Officer | SSale | −10.0K | $12.42 | −$124.2K | −4.7%202.0K after | 10b5-1 |
| Nov 20, 2024 (view filing) | Nov 18 | 2 days | Xynos KonstantinosChief Medical Officer | SSale | −7.25K | $10.78 | −$78.1K | −6.2%109.9K after | |
| Nov 20, 2024 (view filing) | Nov 18 | 2 days | Sarchi ChristopherChief Commercial Officer | SSale | −5.21K | $10.78 | −$56.1K | −5.6%87.0K after | |
| Aug 19, 2024 (view filing) | Aug 16 | 3 days | Hill Emily LuisaChief Financial Officer | SSale | −8.94K | $10.18 | −$91.0K | −8.1%101.1K after | |
| Jun 10, 2024 (view filing) | Jun 7 | 3 days | Xynos KonstantinosChief Medical Officer | SSale | −15.9K | $7.50 | −$119.1K | −11.9%117.1K after | 10b5-1 |
| May 20, 2024 (view filing) | May 16 | 4 days | Sarchi ChristopherChief Commercial Officer | SSale | −2.22K | $6.47 | −$14.4K | −2.3%92.3K after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Schwendenman AndrewChief Accounting Officer | SSale | −2.30K | $6.47 | −$14.9K | −5.7%38.2K after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Love ColinChief Operating Officer | SSale | −17.6K | $6.47 | −$114.0K | −2.2%777.3K after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Astley-Sparke PhilipExecutive Chairman | SSale | −37.9K | $6.47 | −$245.4K | −2.5%1.49M after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Coffin RobertDirector | SSale | −11.5K | $6.47 | −$74.2K | −0.6%1.82M after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Patel SushilChief Executive Officer | SSale | −20.2K | $6.47 | −$130.7K | −8.7%212.0K after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Xynos KonstantinosChief Medical Officer | SSale | −6.37K | $6.47 | −$41.2K | −4.6%133.0K after | |
| Nov 17, 2023 (view filing) | Nov 16 | 1 day | Xynos KonstantinosChief Medical Officer | SSale | −7.31K | $10.92 | −$79.9K | −6.1%112.7K after | |
| Nov 17, 2023 (view filing) | Nov 16 | 1 day | Sarchi ChristopherChief Commercial Officer | SSale | −5.25K | $10.92 | −$57.4K | −6.8%72.2K after | |
| Sep 13, 2023 (view filing) | Sep 11-12 | 2 days | Esposito PamelaChief Business Officer | SSale | −5.66K | $20.01 | −$113.2K | −2.1%263.4K after | 2 lots10b5-1 |
| Aug 24, 2023 (view filing) | Aug 22 | 2 days | Esposito PamelaChief Business Officer | SSale | −18.6K | $20.01 | −$372.2K | −6.6%263.4K after | 10b5-1 |
| Aug 15, 2023 (view filing) | Aug 11 | 4 days | Esposito PamelaChief Business Officer | SSale | −1.40K | $20.00 | −$28.0K | −0.5%263.4K after | 10b5-1 |
| Jul 11, 2023 (view filing) | Jul 10 | 1 day | Esposito PamelaChief Business Officer | SSale | −20.0K | $21.58 | −$431.5K | −7.1%263.4K after | 2 lots10b5-1 |
| Jun 15, 2023 (view filing) | Jun 13 | 2 days | Lewis TanyaChief Dev. Op. Officer | SSale | −12.9K | $24.06 | −$309.4K | −8.7%135.3K after | 2 lots10b5-1 |
| Jun 15, 2023 (view filing) | Jun 13 | 2 days | Patel SushilChief Strategy Officer | SSale | −5.70K | $24.04 | −$137.0K | −3.7%148.9K after | 2 lots10b5-1 |
| May 18, 2023 (view filing) | May 16 | 2 days | Patel SushilChief Strategy Officer | SSale | −15.6K | $18.05 | −$281.1K | −9.2%154.6K after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Coffin RobertPresident & Chief R&D Officer | SSale | −7.86K | $18.05 | −$141.9K | −0.4%1.83M after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Lewis TanyaChief Dev. Op. Officer | SSale | −12.2K | $18.05 | −$220.3K | −7.6%148.2K after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Love ColinChief Operating Officer | SSale | −10.8K | $18.05 | −$194.5K | −1.3%795.0K after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Franchi Jean M.Chief Financial Officer | SSale | −11.4K | $18.05 | −$204.9K | −8.1%128.7K after |